The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study.

Abstract

In a double-blind study versus placebo, the serotonergic agent m-chlorophenylpiperazine (mCPP) was administered to 20 healthy control subjects and 19 migraineurs to investigate the ability of mCPP (0.5 mg/kg) to induce typical migraine attacks. In the following 24 hours there were more migraines after mCPP than after placebo in both groups. These findings are consistent with involvement of 5HT2B,2C,1A receptor subtypes in the pathophysiology of migraine.

• Authors: M Leone, A Attanasio, D Croci, G Filippini, D D'Amico, L Grazzi, A Nespolo, G Bussone
• Journal: Neurology (Neurology) Vol. 55 Issue 1 Pg. 136-9 (Jul 12 2000) ISSN: 0028-3878 [Print] United States
• PMID: 10891925 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Piperazines
• Serotonin Receptor Agonists
• 1-(3-chlorophenyl)piperazine

Topics

• Adult
• Double-Blind Method
• Female
• Humans
• Male
• Migraine Disorders (chemically induced, physiopathology)
• Pain Measurement
• Piperazines (administration & dosage, adverse effects, blood)
• Serotonin Receptor Agonists (administration & dosage, adverse effects, blood)